PRODUCTS & INNOVATION
Key products and innovations are fueling growth and driving the future of health tech.
Jul 17 2019
Our second quarter 2019 is in the books and the momentum keeps accelerating.
With the strength of our product portfolio, including key growth drivers FreeStyle® Libre, MitraClip® and Alinity, we're raising our full-year guidance on the top and bottom lines.
For the quarter, Abbott beat Wall Street estimates on the bottom line with our key products. All four core business units met or exceeded organic sales growth expectations.
We delivered top-tier sales growth of 7.5% on an organic basis (2.7% reported) and adjusted diluted earnings per share (EPS) of 82 cents (56 cents reported).
Looking ahead, we are raising our outlook for 2019 given our accelerating and strong performance. For organic sales, our full-year guidance is 7 to 8% (up from 6.5 to 7.5%)*. For EPS, our guidance is now $3.21 to $3.27 ($2.06 to $2.12 reported), reflecting double-digit growth at the midpoint and adding to an already strong forecast.
And our key products, innovative pipeline and focused execution is driving tremendous growth and shareholder value.
Some of the highlights include:
For full financials, you can read our press release, or take a look at some additional materials below:
Abbott's Chairman and CEO Miles D. White shared his views on second-quarter performance:
Learn more about Abbott's second-quarter 2019 results:
Download a summary of Abbott's earnings highlights here.
For more information on Abbott's earnings results, see the news release.
*Abbott has not provided the GAAP financial measure for organic sales growth on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.
Abbott Q2 Earnings Beat Expectations
Abbott's Tests Helping Tackle the Pandemic
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.